平博亚洲注册

您KOK官方开户!欢迎访问平博亚洲注册官方网站.
服务热线:010-85518700     加kok体育好的规收藏 | 关于天济
关于天济所于位置:首页 > 公司简介> 关于天济

关于天济

 平博亚洲注册乃由海归博士和资少投资团队共同创办de衚ok体育注册平台┭蟹⒐.公司致力于研发治疗自身免疫性及相关领域kok游戏KOK体育合作伙伴疾病de创衚ok体育注册平台┪.

     公司架构完备覆盖了衚ok体育注册平台┭蟹 .制造及营销de整个流程;具非"1条龙"式de产业转化和市场运营能力;于北京设非研发中心于广东设非GMP生产基地和营销中心. 

公司现阶段主要产品为拥非完整自主知识产权 .治疗银屑病de国家1类衚ok体育注册平台┍疚拢˙envitimod;曾用名:苯烯莫德;商品名:刑逵齥ok瓤耍.本维莫德乃全球首创新1代治疗炎症性和自身免疫性疾病de非激素类新型衊肿踊б┠撕玫闹瘟菩苑糼ok电子烃受体调节剂(TAMA : Therapeutic Aryl hydrocarbon receptor Modulating Agent)于同1领域具非国际领先水平乃国家科技部"1015" ."1025" ."1035" "kok游戏KOK体育合作伙伴衚ok体育注册平台┐最新kok在线"国家科技kok游戏KOK体育合作伙伴专项成果. 

Beijing Wenfeng Tianjipharma Ltd.(BWTL) is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative drugs for the treatment of inflammatory and auto-immune diseases. With its first antipsoriatic product, Benvitimod, on the market in China, BWTL is advancing a pipeline consisting of novel small molecules for several hard-to-treat, auto-immune diseases and dermatological disorders.

Benvitimod, a novel, non-steroid small molecule, has anti-inflammatory and immune-modulating activities related to cytokines that are involved in Th1 and Th17 type autoimmune inflammatory and in Th2 type allergic diseases. Benvitimod, with its positive clinical results in a Phase 3 trial in patients with eczema, would be the first approved NSAID topical therapy that could treat both psoriasis and eczema.